SEC Form 4 · accession 0001562180-17-001406
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Magnus Persson
Director
Period of report
Mar 31, 2017
Accepted (ET)
Apr 4, 2017 · 2:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy) | $0.68 | Mar 31, 2017 | A | 12,031 | A | Mar 31, 2017 | Mar 30, 2027 | Common Stock | 12,031 | 12,031 | D |